Analysis of potential predictive factors of clinical benefit in patients (pts) with metastatic colorectal cancer (MCRC) treated with single-agent cetuximab as first-line treatment

被引：0
|
作者：
Gravalos, C.
Sastre, J.
Aranda, E.
Massuti, B.
Vega-Villegas, M. E.
Gomez, A.
Varella-Garcia, M.
Jimeno, A.
Diaz-Rubio, E.
Hidalgo, M.
机构：
[1] Hosp 12 Octubre, Madrid, Spain
[2] Hosp Clin San Carlos, Madrid, Spain
[3] Hosp Reina Sofia, Cordoba, Spain
[4] Hosp Gen Univ Alicante, Alicante, Spain
[5] Hosp Univ Marques de Valdecilla, Santander, Spain
[6] Univ Colorado, Hlth Sci Ctr, Aurora, CO USA
[7] Johns Hopkins Univ, Baltimore, MD USA
[8] Hosp Monteprincipe, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4120
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First-line single-agent cetuximab in patients with advanced colorectal cancer
    Pessino, A.
    Artale, S.
    Sciallero, S.
    Guglielmi, A.
    Fornarini, G.
    Andreotti, I. C.
    Mammoliti, S.
    Comandini, D.
    Caprioni, F.
    Bennicelli, E.
    Andretta, V.
    Siena, S.
    Sobrero, A.
    ANNALS OF ONCOLOGY, 2008, 19 (04) : 711 - 716
  • [2] SINGLE-AGENT CAPECITABINE AS FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
    Davidov, Deyan
    JOURNAL OF IMAB, 2009, 15 (01): : 46 - 49
  • [3] First-line single-agent cetuximab in patients with advanced colorectal cancer.
    Pessino, A.
    Artale, S.
    Guglielmi, A.
    Sciallero, S.
    Fornarini, G.
    Andreotti, I. C.
    Mammoliti, S.
    Marrapese, G.
    Siena, S.
    Sobrero, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 159S - 159S
  • [4] ANALYSIS OF MOLECULAR ALTERATIONS FOR PREDICTING CLINICAL BENEFIT TO CETUXIMAB PLUS CHEMOTHERAPY IN FIRST-LINE METASTATIC COLORECTAL CANCER (MCRC)
    Javier, Sastre
    Patricia, Llovet
    Julian, Sanz
    Inmaculada, Bando
    Milagros, Ferrer
    Alfonso Pilar, Garcia
    Olga, Donnay
    Alfredo, Carrato
    Ana, Jimenez-Gordo
    Enrique, Aranda
    Ana, Leon
    Cristina, Gravalos
    Juan Carlos, Camara
    Jaime, Feliu
    Beatriz, Sanchiz
    Trinidad, Caldes
    Eduardo, Diaz-Rubio
    ANNALS OF ONCOLOGY, 2014, 25
  • [5] Cetuximab and capecitabine as first-line treatment for elderly patients (pts) with metastatic colorectal cancer (mCRC): Preliminary results of TTD trial
    Gravalos, C.
    Rivera, F.
    Massuti, B.
    Sastre, J.
    Marcuello, E.
    Valladares, M.
    Gil, S.
    Abad, A.
    Diaz-Rubio, E.
    Aranda, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] First-Line Maintenance Treatment in Metastatic Colorectal Cancer (mCRC): Quality and Clinical Benefit Overview
    Martin-Richard, Marta
    Tobena, Maria
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (03) : 1 - 13
  • [7] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (Pts) with metastatic colorectal cancer (MCRC)
    Laudani, A.
    Savio, G.
    Leonardi, V.
    Palmisano, V.
    Tartaglia, L.
    Manuguerra, G.
    Pepe, A.
    Alu, M.
    Usset, A.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 6 - 6
  • [8] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (PTS) with metastatic colorectal cancer (MCRC)
    Laudani, Agata
    Savio, Giuseppina
    Leonardi, Vita
    Palmisano, Valentina
    Rondello, Giacomo
    Alu, Massimiliano
    Pepe, Alessio
    Calabria, Caterina
    Usset, Antonella
    Agostara, Biagio
    ANNALS OF ONCOLOGY, 2006, 17 : 119 - 119
  • [9] CETUXIMAB FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Rodriguez, R.
    Beltran, C.
    VALUE IN HEALTH, 2011, 14 (07) : A433 - A434
  • [10] Cetuximab for the first-line treatment of metastatic colorectal cancer
    Meads, C.
    Round, J.
    Tubeuf, S.
    Moore, D.
    Pennant, M.
    Baylis, S.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 1 - 8
12345